The FINANCIAL -- The Management Board of the Krka public limited company on November 5 held a press conference to present the business results of the Krka Company and Krka Group for January to September 2009 and plans for next 5 year period, which were also discussed by the Supervisory Board at its meeting yesterday.

The FINANCIAL -- Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced on November 5 the commercial launch of VIBATIV (telavancin) in the United States.

The FINANCIAL -- Bristol-Myers Squibb Company (NYSE: BMY) on November 5 announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for REYATAZ to include long-term data from the CASTLE Study.

The FINANCIAL -- Amgen (Nasdaq: AMGN) on November 5 announced that the Phase 3 PRIME "203" trial evaluating Vectibix?? (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.

The FINANCIAL -- King Pharmaceuticals, Inc. (NYSE:KG) announced on November 5 that total revenues were $463 million during the third quarter ended September 30, 2009, compared to $388 million in the third quarter of 2008.